Dark Forest Capital Management LP Invests $308,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Dark Forest Capital Management LP acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 7,460 shares of the company’s stock, valued at approximately $308,000.

A number of other hedge funds have also recently made changes to their positions in the business. Summit Investment Advisors Inc. lifted its holdings in shares of Mirum Pharmaceuticals by 8.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company’s stock worth $172,000 after acquiring an additional 312 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Mirum Pharmaceuticals by 100.0% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock worth $30,000 after acquiring an additional 357 shares during the last quarter. Legato Capital Management LLC lifted its holdings in shares of Mirum Pharmaceuticals by 7.9% in the 4th quarter. Legato Capital Management LLC now owns 13,395 shares of the company’s stock worth $554,000 after acquiring an additional 977 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Mirum Pharmaceuticals by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock worth $421,000 after acquiring an additional 1,003 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Mirum Pharmaceuticals by 2.4% in the fourth quarter. Rhumbline Advisers now owns 53,113 shares of the company’s stock worth $2,196,000 after buying an additional 1,236 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Robert W. Baird lifted their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research note on Thursday, February 27th. HC Wainwright lifted their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals has an average rating of “Buy” and a consensus price target of $58.20.

Insider Activity

In other news, CEO Christopher Peetz sold 27,279 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the sale, the chief executive officer now owns 138,641 shares in the company, valued at approximately $6,129,318.61. The trade was a 16.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Peter Radovich sold 2,627 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $126,673.94. Following the sale, the chief operating officer now owns 26,961 shares in the company, valued at approximately $1,300,059.42. This trade represents a 8.88 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,557 shares of company stock worth $4,726,040. Corporate insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Stock Up 1.3 %

Shares of Mirum Pharmaceuticals stock opened at $41.31 on Tuesday. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The company’s fifty day simple moving average is $43.90 and its two-hundred day simple moving average is $44.06. The company has a market cap of $2.04 billion, a P/E ratio of -20.45 and a beta of 1.00. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.83 and a 12-month high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). The company had revenue of $99.41 million for the quarter, compared to analysts’ expectations of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. Research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.